Counting Colonies
Scott Sutton,
Ph.D.
Vectech
Pharmaceutical Consultants
This article first appeared in the
PMF Newsletter
of September, 2006 and is protected by copyright to PMF.
It appears here with permission.
Who Cares?
What is the fuss about in determining the number of colony
forming units? After all, the CFU is only an estimate of the
number of cells present. It is a skewed estimate at best as the
only cells able to form colonies are those that can grow under
the conditions of the test (incubation media, temperature, time,
oxygen conditions, etc). Even among that group of microorganisms
a colony does not represent a single cell, but rather cells that
happened to be well separated on the plate and so can be
distinguished after growth. A colony could arise from one cell,
or several thousand. So why the fuss?
One reason for concern is that microbiology has a
well-deserved reputation for being highly variable. Our lax
attention to precision and accuracy in our measurements helps
further this perception. We have allowed specifications for
environmental monitoring, raw material bioburden, in-process
bioburden and finished product bioburden to be imposed by
regulation without regard for the ability of the method to
support those specifications.
A second reason for concern is that now we are trying to
introduce alternate microbiological methods into the lab. Being
obsessive by training, we are trying to exceed measures of
accuracy and precision in this exercise that the traditional
methods cannot come close to matching. A good example of this is
the Pharm Eur “Precision” requirement for an alternate method
(quantification) to have a Relative Standard Deviation (RSD) in
the range of 10-15% (1). While you might get lucky and hit this
with dilutions whose plate counts are in the 150-250 CFU/plate
range, - at lower plate counts this target value imposed by
regulation will virtually guarantee a long, difficult and quite
possibly unsuccessful, validation exercise.
Countable Range on a Plate
Literature
The general ranges in common acceptance for countable numbers
of colonies on a plate are 30 – 300 and 25 – 250. The origin of
those ranges is worth examination. Breed and Dotterrer published
a seminal paper on this topic in 1916 (2). They set out to
determine the “limit in the number of colonies that may be
allowed to grow on a plate without introducing serious errors…in
connection with the proposed revisions of standard methods of
milk analysis.” They note that “the kind of bacteria in the
material under examination will have an influence on the size of
the colonies, and consequently, on the number that can develop
on a plate.” They also note that food supply can be an issue,
that colonies close to each other on the plate may merge, and
that neighbor colonies may inhibit growth or conversely
stimulate growth. “Because of these and other difficulties
certain plates in any series made from a given sample are more
satisfactory for use in computing a total than are others. The
matter of selecting plates to be used in computing a count
becomes therefore a matter requiring considerable judgment.”
Breed and Dotterrer chose their countable plates from
triplicate platings of each dilution, requiring acceptable
plates to be within 20% of the average. On this analysis, plates
with more than 400 CFU were unsatisfactory, as were those of
less than 30 CFU, with best results in the range of 50-200 CFU/plate.
The major paper from Tomasiewicz et al (3) provides an
excellent review of the continued evolution of the appropriate
number of CFU per plate from milk. They took data from colony
counts of raw milk from three different experiments (each
dilution plated in triplicate) and used to determine a
mean-squared-error of the estimate for all plates. Their
recommendation at the end of the study was for a countable range
of 25-250 CFU/plate in triplicate. It is interesting to note
that although the authors note that CFU follow a Poisson
distribution, no mention is made of any data transformation used
to approximate a normal distribution prior to the use of normal
statistical analytical tools. Tomasiewicz et al provide
excellent cautionary advice:
“The data presented herein are not necessarily applicable
to other systems. For automated equipment, the optimum range
may well vary with the instrument…Furthermore, even if
automation is not used appropriate numbers of colonies that
should be on a countable plate can very widely, depending on
many other variables. With soil fungi for example…”
The compendia have recently harmonized a microbial
enumeration test (4), and in this test recommend that the
technician “Select the plates corresponding to a given dilution
and showing the highest number of colonies less than 250 for
TAMC and 50 for TYMC.” In determination of the resistance of
biological indicators, USP recommends a range of “20 to 300
colonies, but not less than 6” (5). However, the most complete
description of the countable range is found in the informational
chapter <1227> (6):
“The accepted range for countable colonies on a standard
agar plate is between 25 and 250 for most bacteria and
Candida albicans. This range was established in the food
industry for counting coliform bacteria in milk. The range
is acceptable for compendial organisms, except for fungi. It
is not optimal for counting all environmental monitoring
isolates. The recommended range for Aspergillus niger
is between 8 to 80 cfu per plate. The use of membrane
filtration to recover challenge organisms, or the use of
environmental isolates as challenge organisms in the
antimicrobial effectiveness testing, requires validation of
the countable range.”
ASTM provides countable ranges of 20-80 CFU/membrane, 20-200
for spread plates and 30-300 for pour plates (7). The FDA
Bacterial Analytical Manual (BAM) recommends 25-250 CFU/plate as
a countable range (8).
Upper Limit
The upper limit of plate counts is dependent on a number of
factors, as described previously. The major issues include the
colony size and behavior (swarming?), and the surface area of
the plate. The size particularly comes into play with plating a
membrane for determination of CFU as the surface area of that
membrane is so much smaller than that of a standard plate.
TNTC can be reported out several ways. ASTM (7) recommends
reporting this out as >”upper limit”. For example, a 1:10
dilution with more than 200 CFU on a spread plate would be
reported as “>2,000 CFU/mL (or gram). FDA’s BAM recommends
counting the colonies from the dilution with plates giving
counts closest to 250, counting a portion of the plate,
estimating the total number and then using that number as the
Estimated Aerobic Count. It is not clear to the author how this
is greatly superior to guessing. In my opinion this is an
invalid plating and needs to be done correctly at a later date
(note I am strenuously avoiding the use of the word retest. This
result invalidates the plating and therefore the test was not
performed correctly.) I know this is a hardship to the lab, who
were trying to reduce the plating load initially by not plating
out sufficient dilutions. However, making a mistake initially is
not a reasonable excuse to avoid doing it correctly after the
mistake is recognized. If the lab wishes to use this “estimated
count” it should, at a minimum, have it clearly described in
their “counting CFU” SOP with a rationale as to when the plate
counts are not critical and can be estimated in this fashion.
There are methods available if you should want to accurately
determine the upper limit for a unique plating surface or a
unique colony type. One is presented in the USP informational
chapter <1227> (5) which is based on a pair-wise comparison of
counts from a dilution series. This is based on the assumption
that at the upper limit the observed numbers of CFU will fall
off the expected numbers at some point (see Figure 1). This
divergence will become significant at some point – that defines
the upper limit of CFU/plate.
Figure 1. Difference
between Expected and Observed CFU
with Increasing Numbers
Lower Limit
A central concern in this determination is the reporting of
the Limit of Quantification (which is what we are really
interested in reporting) against the Limit of Detection (1 CFU).
This is an important distinction if we are being held to
specifications in the lower range.
ASTM recommendations focus on the LOD, and urge the user to
report that answer out if no colonies are recovered (ie <10 CFU/mL
for a 1:10 dilution) (7). If countable colonies are present, but
below the countable range, count them anyway and report an
estimated count.
USP (6) does not have a specific recommendation on how to
report out these low numbers, but does note “Lower counting
thresholds for the greatest dilution plating in series must be
justified.”
FDA BAM (8) recommends a different reporting format. In the
FDA BAM method, all counts are recorded in the raw data, but the
information is reported out as <LOQ. For example, a 1:100
dilution that yields counts of 18 and 12 would be reported out
as <2,500. This is, in my opinion, the prudent course. The crux
of the argument is that experiment studies have shown very poor
accuracy in plate counts below 25 (see above). Theoretically we
can argue that since the CFU follow the Poisson distribution,
the error of the estimate is the square root of the average (USP
<1227>). This leads to graphs such as in Figure 2 which shows us
that as the CFU/plate drops below the countable range, the error
as a percent of the mean increases rapidly. This confusion
between the Limit of Detection and the Limit of Quantification
for plate counts has led to some very difficult situations (as
discussed below).
Figure 2. Increase in
Error with Decreasing Numbers
Unusual Situations
What About Two Dilutions with Countable Colonies?
Ideally you would never see two separate dilutions with
counts in the countable range, as the countable ranges cover a
ten-fold range of CFU. However, this is microbiology. ASTM
recommendations (7) urge you to take both dilutions into
account, determining the CFU/mL (or gram) separately for each,
then averaging the results for the final result. Breed and
Dotterrer (2) also used several dilutions if the numbers fit the
QC requirements (see below). FDA BAM has no recommendations in
this situation.
While the argument can be made to use all counts, this is a
stronger argument if triplicate plates are used and QC limits
are in place to discard erroneous plates.
A strong argument can also be made to take the dilution
providing the larger number of CFU in the countable range. This
approach minimizes two concerns, that the errors in the
estimates increase with increasing serial dilutions, and that
the error in the estimate increases with decreasing plate
counts. Use of the smaller dilution (eg 1:10 vs 1:100) could be
justified from this perspective.
Whichever method used should be documented and justified in
the “Counting CFU” SOP.
What about QC Limits on Replicate Plate Counts?
Periodically there are recommendations to establish Quality
Control limits on replicate plate counts. Breed and Dotterrer in
their 1916 paper (2) required valid plate counts from triplicate
plates to provide estimates of CFU/mL within 20% of the mean. In
other words, all plates were counted, each plate’s CFU count was
used to estimate the original CFU/mL, then each estimate was
evaluated. If the individual plate’s estimate was within 20% of
the mean, it was deemed acceptable. This method is not practical
in the QC lab.
Establishment of QC limits for plate counts works best if you
have at least three replicate plates for each dilution. The
average of the dilution replicates can be determined, variant
counts (hopefully no more than one plate per triplicate plating)
discarded and the final average determined. If you try this with
duplicate plates you frequently end up with trying to average
the results of one plate. While this method looks good on paper,
the prudent lab manager will evaluate some historical data
before instituting it as a practice.
The method used to QC individual plate counts, if used,
should be documented and justified in SOP, along with the
response to finding variant counts.
Can I plate 10 1 mL samples to plate a Total of One 10 mL
Sample?
There have been suggestions that a larger volume of material
may be plated across several plates, and the results reported
out for the larger volume. For example, plating 10 1 mL samples
on 10 different plates, and then reporting it as if a 10 mL
sample was plated. This approach is flawed in that it ignores
several sources of variability in plating including sampling
error, plating errors, growth/incubation error and counting
errors (9, 10). The correct interpretation for this situation
that you have just plated 1 mL ten times, not 10 mL once. The
numbers might be averaged, they cannot be added.
Rounding and Averaging
To discuss this we need to determine what the significant
figures might be in the measure. For raw colony counts, common
practice determines that the CFU observed determine the
significant figure, and that the average is one decimal to the
right of that number (sticklers for accuracy will report the
geometric mean rather than the arithmetic mean given the Poisson
distribution followed by CFU). In reporting, it is common
practice to report out as scientific notation using two
significant figures. This requires rounding.
USP (11) and ASTM (7) both round up at five if 5 is the
number to the right of the last significant figure. FDA BAM has
a more elaborate scheme, rounding up if the number is 6 or
higher, down if 4 or lower. If the number is 5, BAM looks to the
next number to the right and rounds up if it is odd, down if it
is even.
This is one of those situations where you want every-one to
do the calculations the same way (I am hard pressed to come up
with a situation in a lab where you want everyone to do it
differently). Be sure to include direction and its justification
in the “Counting CFU” SOP if it does not already exist in a
separate SOP.
Impact on Specifications and Environmental Monitoring
Control Levels
We are back to the question of WHO CARES?
If you are faced with a finished product bioburden of NMT
(Not More Than) 100 CFU/gram, and your method suitability study
requires a 1:100 dilution of the product to overcome any
antimicrobial effects, then how are you to test it? Common
practice is to perform the 1:100 dilution, perform a pour plate
of 1 mL in duplicate and if 2 colonies grow on each plate, the
product fails specification. This common practice is
scientifically unsupportable – it confused the Limit of
Detection with the Limit of Quantification for the plate count
method.
Let’s take a look at environmental monitoring alert and
action levels for aseptically produced products. Hussong and
Madsen (12) recently published a thoughtful review of this topic
where they argue that the levels of acceptable CFU for many room
classifications are below the noise level of plate count
technology (eg in the range of 1-2 CFU/m3). In addition,
environmental data can be extremely variable, much more so than
controlled lab studies as the numbers of microorganisms, the
physiological state of the isolates, even the species are
completely out of the control of the investigator. In addition
the numbers do not conform to a normal distribution as there are
sporadic counts with a count of “zero” CFU predominating. They
conclude that since the numbers are unreliable, the trend in the
data is the only important consideration, and that EM counts
cannot be used for product release criteria. A separate
treatment of this subject was presented by Farrington (13) who
argues that the relationship between EM data and finished
product quality is a widely held, but unproven belief,
compounded by the problems in accuracy with the low counts
generated by plate count methodology.
Conclusions
In conclusion, all methods have limitations. One of the major
limitations to the plate count method is the relatively narrow
countable range (generally considered to be 25-250 CFU bacteria
on a standard petri dish). The currently prevailing confusion
between the Limit of Detection (1 CFU) and Limit of
Quantification (25 CFU) for the plate count method creates a
larger degree of variability in microbiology data than is
necessary. An unfortunate regulatory trend in recent years is to
establish expectations (specifications, limits, levels) for data
generated by the plate count method that the accuracy of the
method cannot support. This is a real opportunity for
modification of current practice to approach the goal of
“science-based regulations”.
References
- Pharm Eur. 2006. 5.1.6 Alternative Methods for Control
of Microbiological Quality. Pharm Eur vol.5.5 pp
4131-4142.
- Breed, R and WD Dotterrer. 1916. The Number of Colonies
Allowable On Satisfactory Agar Plates. J Bacteriol.
1:321-331.
- Tomasiewicz, D.M.et al. 1980. The Most Suitable
Number of Colonies On Plates for Counting. J Food Prot.
43(4):282-286.
- USP. 2006. <61> Microbial Examination of Nonsterile
Products: Microbial Enumeration Tests. USP 29 Suppl 2.
August 1, 2006 . United States Pharmacopeial Convention. pp.
3757-3759.
- USP. 2006. <55> Biological Indicators – Resistance
Performance Tests. USP 29. United States
Pharmacopeial Convention. pp. 2501-2503.
- USP. 2006. <1227> Validation of Microbial Recovery from
Pharmacopeial Articles. USP 29. United States
Pharmacopeial Convention. pp. 3053-3055.
- ASTM. 1998. D5465-93(1998) Standard Practice for
Determining Microbial Colony Counts from Waters Analyzed by
Plating Methods
- FDA. 2001. Chapter 3 – Aerobic Plate Count In
Bacteriological analytical Manual Online at
http://www.cfsan.fda.gov/~ebam/bam-3.html#6-International
- Jennison, MW and GP Wadsworth. 1940. Evaluation of the
Errors Involved In Estimating Bacterial Numbers by the
Plating Method. J Bacteriol. 39:389-397.
- Weenk, G.H. 1992. Microbiological Assessment of Culture
Media: Comparison and Statistical Evaluation of Methods.
Int J Food Microbiol. 17:159-181.
- USP. 2006.General Notices: Significant Figures and
Tolerances. USP 29. United States Pharmacopeial
Convention. p. 4.
- Hussong, D and RE Madsen. 2004. Analysis of
Environmental Microbiology Data From Cleanroom Samples.
Pharm Technol. Aseptic Proc Issue: 10-15.
- Farrington, JK. 2005. Environmental Monitoring in
Pharmaceutical Manufacturing - A Product Risk Issue. Amer
Pharm Rev. 8(4):26-30.
Consulting with Scott Sutton
|